Proactive Investors - Run By Investors For Investors

Award-winning pain consultant appointed to Sativa Investments’ advisory board

“The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients. Matthew's qualifications and research in this area add even further to the input of Sativa's top-level Medicinal Cannabis Advisory Board.”
cannabis
Sativa is the UK’s first medical cannabis investment vehicle

Sativa Investments PLC (NEX:SATI) has appointed an award-winning pain medicine and anaesthetic consultant to its medical cannabis advisory board.

Matthew Brown is a consultant at the Royal Marsden hospital in West London and recently published research into using cannabinoids for cancer pain treatment.

READ: Sativa announces £3.75mln equity raise

Last month, the UK government gave doctors the green light to prescribe cannabis products to patients for the first time ever.

“The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients,” said founder and chief executive Geremy Thomas.

“Matthew's qualifications and research in this area add even further to the input of Sativa's top-level Medicinal Cannabis Advisory Board. Patient outcome is the clear driver in the highly sensitive and prevalent area of cancer treatment.”

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
cancer
May 14 2018
Physiomics' share price surged on a €500,000 contract for its virtual tumour software with Merck KgaA.
CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use